Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management
The unprecedented progress in addressing unmet needs in haemophilia care to date includes developing several novel therapies that rebalance haemostasis by restoring thrombin generation in patients with haemophilia A or B with and without inhibitors. These novel therapies are FVIII mimetics, antithro...
Main Author: | Johnny N. Mahlangu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.670526/full |
Similar Items
-
Non‐factor therapies for bleeding disorders: A primer for the general haematologist
by: Dawn Swan, et al.
Published: (2022-08-01) -
"Relation of Factor VIII and IX Inhibitors with ABO Blood Groups in 150 Patients with Haemophilia A and B "
by: Hassan Mansouri Torghabeh, et al.
Published: (2006-03-01) -
European principles of inhibitor management in patients with haemophilia
by: P. L. F. Giangrande, et al.
Published: (2018-04-01) -
Advances in the management of haemophilia: emerging treatments and their mechanisms
by: Dide Okaygoun, et al.
Published: (2021-09-01) -
An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database
by: Marc Trossaërt, et al.
Published: (2024-12-01)